{"transactions":[{"id":737895,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:30:22.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":19188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":19188,"derivative":{"exercise_price":24.11,"expiration_date":"2036-06-10","underlying":"Common Shares","underlying_shares":19188},"source":{"system":"sec-edgar","filing":"0001193125-26-271164","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271164/ownership.xml","form_type":"4"}},{"id":737894,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-15T20:30:22.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":4666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date."}],"balance_after":24289,"source":{"system":"sec-edgar","filing":"0001193125-26-271164","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271164/ownership.xml","form_type":"4"}},{"id":1109861,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:30:05.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":75187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":75187,"derivative":{"exercise_price":7.3,"expiration_date":"2035-06-11","underlying":"Common Shares","underlying_shares":75187},"source":{"system":"sec-edgar","filing":"0000950170-25-086764","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025086764/ownership.xml","form_type":"4"}},{"id":1482186,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T20:13:58.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":16506,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":16506,"derivative":{"exercise_price":7.25,"expiration_date":"2034-06-09","underlying":"Common Shares","underlying_shares":16506},"source":{"system":"sec-edgar","filing":"0000950170-24-072454","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024072454/ownership.xml","form_type":"4"}},{"id":1845353,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-23T21:53:13.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":19203,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option shall vest in twelve (12) equal monthly installments starting from the grant date or upon the next Annual Meeting date, if earlier, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the\" Reverse Stock Split\"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":27267,"derivative":{"exercise_price":3.61,"expiration_date":"2033-06-20","underlying":"Common Shares","underlying_shares":19203},"source":{"system":"sec-edgar","filing":"0000899243-23-016423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924323016423/doc4.xml","form_type":"4"}},{"id":1845352,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-06-23T21:53:13.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":13671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one Common Share of the Issuer. The RSUs shall vest in four (4) equal quarterly installments from the grant date or upon the next Annual Meeting date, if earlier, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the\" Reverse Stock Split\"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":19623,"source":{"system":"sec-edgar","filing":"0000899243-23-016423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924323016423/doc4.xml","form_type":"4"}},{"id":1972177,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-03T09:18:59.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares."}],"balance_after":0,"derivative":{"exercise_price":12.15,"expiration_date":"2031-01-26","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001385508-23-000069","document":"wf-form4_167785312619410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550823000069/wf-form4_167785312619410.xml","form_type":"4"}},{"id":1972176,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-03T09:18:59.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":27250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares."}],"balance_after":0,"derivative":{"exercise_price":13.6,"expiration_date":"2030-01-07","underlying":"Common Stock","underlying_shares":27250},"source":{"system":"sec-edgar","filing":"0001385508-23-000069","document":"wf-form4_167785312619410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550823000069/wf-form4_167785312619410.xml","form_type":"4"}},{"id":1972175,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-03T09:18:59.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":13200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares."}],"balance_after":0,"derivative":{"exercise_price":14.62,"expiration_date":"2029-01-14","underlying":"Common Stock","underlying_shares":13200},"source":{"system":"sec-edgar","filing":"0001385508-23-000069","document":"wf-form4_167785312619410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550823000069/wf-form4_167785312619410.xml","form_type":"4"}},{"id":1972174,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option","published_at":"2023-03-03T09:18:59.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares."}],"balance_after":0,"derivative":{"exercise_price":6,"exercise_date":"2013-12-31","expiration_date":"2023-12-30","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001385508-23-000069","document":"wf-form4_167785312619410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550823000069/wf-form4_167785312619410.xml","form_type":"4"}},{"id":1972173,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option","published_at":"2023-03-03T09:18:59.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares."}],"balance_after":0,"derivative":{"exercise_price":7.25,"exercise_date":"2015-10-27","expiration_date":"2025-10-26","underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001385508-23-000069","document":"wf-form4_167785312619410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550823000069/wf-form4_167785312619410.xml","form_type":"4"}},{"id":1972172,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option","published_at":"2023-03-03T09:18:59.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares."}],"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2014-06-15","expiration_date":"2024-06-14","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001385508-23-000069","document":"wf-form4_167785312619410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550823000069/wf-form4_167785312619410.xml","form_type":"4"}},{"id":1972171,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option","published_at":"2023-03-03T09:18:59.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares."}],"balance_after":0,"derivative":{"exercise_price":6,"exercise_date":"2013-12-31","expiration_date":"2023-12-30","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001385508-23-000069","document":"wf-form4_167785312619410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550823000069/wf-form4_167785312619410.xml","form_type":"4"}},{"id":1972170,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-03T09:18:59.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":6667,"price":20,"value":133340.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 6,667 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001385508-23-000069","document":"wf-form4_167785312619410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550823000069/wf-form4_167785312619410.xml","form_type":"4"}},{"id":1972169,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-03T09:18:59.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"6,667 shares are represented by performance stock units (\"PSUs\"), the vesting of which accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer."}],"balance_after":6667,"source":{"system":"sec-edgar","filing":"0001385508-23-000069","document":"wf-form4_167785312619410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550823000069/wf-form4_167785312619410.xml","form_type":"4"}},{"id":1972168,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock par value $0.001","published_at":"2023-03-03T09:18:59.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":5100,"price":20,"value":102000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the \"Merger Agreement\"), in exchange for a cash payment of $20.00 per share without interest thereon (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001385508-23-000069","document":"wf-form4_167785312619410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550823000069/wf-form4_167785312619410.xml","form_type":"4"}},{"id":1972167,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-03T09:18:59.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":37901,"price":20,"value":758020.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 37,901 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001385508-23-000069","document":"wf-form4_167785312619410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550823000069/wf-form4_167785312619410.xml","form_type":"4"}},{"id":1972166,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-03T09:18:59.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":37438,"price":20,"value":748760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the \"Merger Agreement\"), in exchange for a cash payment of $20.00 per share without interest thereon (the \"Merger Consideration\")."}],"balance_after":37901,"source":{"system":"sec-edgar","filing":"0001385508-23-000069","document":"wf-form4_167785312619410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550823000069/wf-form4_167785312619410.xml","form_type":"4"}},{"id":2040050,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-31T16:22:43.000Z","date":"2023-01-27","kind":"sale","acquired":false,"shares":1358,"price":20.26,"value":27513.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":75339,"source":{"system":"sec-edgar","filing":"0001385508-23-000034","document":"wf-form4_167520015002042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550823000034/wf-form4_167520015002042.xml","form_type":"4"}},{"id":2058516,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-09T17:09:24.000Z","date":"2023-01-09","kind":"sale","acquired":false,"shares":1183,"price":20.2,"value":23896.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":76697,"source":{"system":"sec-edgar","filing":"0001385508-23-000018","document":"wf-form4_167330214981696.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550823000018/wf-form4_167330214981696.xml","form_type":"4"}},{"id":2061873,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-05T16:52:01.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":5029,"price":20.2,"value":101585.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":77880,"source":{"system":"sec-edgar","filing":"0001385508-23-000005","document":"wf-form4_167295549954717.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550823000005/wf-form4_167295549954717.xml","form_type":"4"}},{"id":2185743,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director's Deferred Share Units","published_at":"2022-08-16T01:55:15.000Z","date":"2022-08-11","kind":"grant","acquired":true,"shares":503773,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."}],"balance_after":503773,"derivative":{"underlying":"Common Shares"},"source":{"system":"sec-edgar","filing":"0000899243-22-028728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322028728/doc4.xml","form_type":"4"}},{"id":2185742,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-16T01:55:15.000Z","date":"2022-08-11","kind":"grant","acquired":true,"shares":120968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The option grant has an exercise price of $0.84 Canadian Dollars. This represents the exercise price in United States Dollars."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option shall vest and become exercisable 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date."}],"balance_after":120968,"derivative":{"exercise_price":0.66,"expiration_date":"2032-08-10","underlying":"Common Shares","underlying_shares":120968},"source":{"system":"sec-edgar","filing":"0000899243-22-028728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322028728/doc4.xml","form_type":"4"}},{"id":2185741,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-08-16T01:55:15.000Z","date":"2022-08-11","kind":"grant","acquired":true,"shares":89286,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one Common Share of the Issuer. These RSUs will vest in three equal annual installments over such three-year period; provided, that in the event that the Reporting Person's continuous service as a member of the Board terminates for any reason other than for cause after the first anniversary of the grant date, a portion of these RSUs that would have vested on the next annual vesting date following the date of departure will immediately vest in full as of the date of termination of service on a prorated basis."}],"balance_after":89286,"source":{"system":"sec-edgar","filing":"0000899243-22-028728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322028728/doc4.xml","form_type":"4"}},{"id":2206826,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-15T16:03:19.000Z","date":"2022-07-14","kind":"sale","acquired":false,"shares":2246,"price":11.11,"value":24953.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were sold to cover tax withholding obligations in connection with the vesting of performance stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $10.80 to $11.53. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":82909,"source":{"system":"sec-edgar","filing":"0001385508-22-000109","document":"wf-form4_165791538445805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550822000109/wf-form4_165791538445805.xml","form_type":"4"}},{"id":2219244,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-29T16:06:06.000Z","date":"2022-06-27","kind":"grant","acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the acquisition of shares upon the determination on June 27, 2020 by the Compensation and Human Capital Committee of the Board of Directors of the Issuer that the performance conditions were met with respect to a portion of the performance stock units granted to the Reporting Person on January 4, 2022."}],"balance_after":85155,"source":{"system":"sec-edgar","filing":"0001385508-22-000103","document":"wf-form4_165653315033706.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550822000103/wf-form4_165653315033706.xml","form_type":"4"}},{"id":2423845,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-27T16:03:52.000Z","date":"2022-01-27","kind":"sale","acquired":false,"shares":1995,"price":26.15,"value":52169.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $25.60 to $26.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":78488,"source":{"system":"sec-edgar","filing":"0001385508-22-000025","document":"wf-form4_164331741572395.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550822000025/wf-form4_164331741572395.xml","form_type":"4"}},{"id":2436538,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-12T16:29:04.000Z","date":"2022-01-10","kind":"sale","acquired":false,"shares":1058,"price":30.49,"value":32258.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $28.81 to $30.79. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":80483,"source":{"system":"sec-edgar","filing":"0001385508-22-000020","document":"wf-form4_164202292443156.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550822000020/wf-form4_164202292443156.xml","form_type":"4"}},{"id":2442988,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-05T16:15:16.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"40,000 shares are represented by restricted stock units (\"RSUs\"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-third of the RSUs vest on the anniversary dates of January 4, 2023, January 4, 2024 and January 4, 2025, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":81541,"source":{"system":"sec-edgar","filing":"0001385508-22-000008","document":"wf-form4_164141729075458.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550822000008/wf-form4_164141729075458.xml","form_type":"4"}},{"id":2567391,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock par value $0.001","published_at":"2021-09-16T16:12:01.000Z","date":"2021-09-16","kind":"purchase","acquired":true,"shares":100,"price":23.44,"value":2344.0,"ownership":{"direct":true},"balance_after":5100,"source":{"system":"sec-edgar","filing":"0001385508-21-000134","document":"wf-form4_163182310785742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550821000134/wf-form4_163182310785742.xml","form_type":"4"}},{"id":2893257,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-27T16:23:11.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On January 26, 2021, the reporting person was granted an option to purchase 31,250 shares of common stock. The option vests as follows: 1/48 of the options become exercisable on the first monthly anniversary of January 26, 2021, the vesting commencement date, and 1/48 of the options become exercisable on such date every month thereafter through the fourth year anniversary of the vesting commencement date."}],"balance_after":31250,"derivative":{"exercise_price":12.15,"expiration_date":"2031-01-26","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001385508-21-000019","document":"wf-form4_161178257624242.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550821000019/wf-form4_161178257624242.xml","form_type":"4"}},{"id":2893256,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-01-27T16:23:11.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":15650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"15,650 shares are represented by restricted stock units (\"RSUs\"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-fourth of the RSUs vest on the anniversary dates of January 26, 2022, January 26, 2023, January 6, 2024 and January 26, 2025, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":41541,"source":{"system":"sec-edgar","filing":"0001385508-21-000019","document":"wf-form4_161178257624242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550821000019/wf-form4_161178257624242.xml","form_type":"4"}},{"id":2893255,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-01-27T16:23:11.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":3766,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"3,766 shares are represented by restricted stock units (\"RSUs\"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. 100% of the RSUs vest on the anniversary dates of January 26, 2022, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":25891,"source":{"system":"sec-edgar","filing":"0001385508-21-000019","document":"wf-form4_161178257624242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550821000019/wf-form4_161178257624242.xml","form_type":"4"}},{"id":3314352,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-01-09T16:07:40.000Z","date":"2020-01-07","kind":"grant","acquired":true,"shares":27250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 7, 2020, the reporting person was granted an option to purchase 27,250 shares of common stock. The option vests as follows: 1/48 of the options become exercisable on the first monthly anniversary of the vesting commencement date, and 1/48 of the options become exercisable on such date every month thereafter through the fourth year anniversary of the Grant Date."}],"balance_after":27250,"derivative":{"exercise_price":13.6,"expiration_date":"2030-01-07","underlying":"Common Stock","underlying_shares":27250},"source":{"system":"sec-edgar","filing":"0001385508-20-000011","document":"wf-form4_157860404223396.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550820000011/wf-form4_157860404223396.xml","form_type":"4"}},{"id":3314351,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-01-09T16:07:40.000Z","date":"2020-01-07","kind":"grant","acquired":true,"shares":13650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"13,650 shares are represented by restricted stock units (\"RSUs\"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-fourth of the RSUs vest on the anniversary dates of January 7, 2021, January 7, 2022, January 7, 2023 and January 7, 2024, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":22125,"source":{"system":"sec-edgar","filing":"0001385508-20-000011","document":"wf-form4_157860404223396.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550820000011/wf-form4_157860404223396.xml","form_type":"4"}},{"id":3560094,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option","published_at":"2019-04-08T17:07:32.000Z","date":"2019-04-05","kind":"exercise","acquired":false,"shares":21472,"price":7.25,"value":155672.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of three trials on or subsequent to October 23, 2015; or (B) (1) the approval by the U.S. Food and Drug Administration of the New Drug Application with respect to the opioid overdose reversal treatment; and (2) the commencement of two trials on or subsequent to October 23, 2015; and (ii) the Expiration Date."}],"balance_after":375000,"derivative":{"exercise_price":7.25,"exercise_date":"2015-10-27","expiration_date":"2025-10-26","underlying":"Common Stock","underlying_shares":21472},"source":{"system":"sec-edgar","filing":"0001385508-19-000039","document":"wf-form4_155475763759980.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000039/wf-form4_155475763759980.xml","form_type":"4"}},{"id":3560093,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-04-08T17:07:32.000Z","date":"2019-04-08","kind":"sale","acquired":false,"shares":12772,"price":12.1,"value":154541.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $12.06 to $12.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":8475,"source":{"system":"sec-edgar","filing":"0001385508-19-000039","document":"wf-form4_155475763759980.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000039/wf-form4_155475763759980.xml","form_type":"4"}},{"id":3560092,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-04-08T17:07:32.000Z","date":"2019-04-05","kind":"sale","acquired":false,"shares":16001,"price":11.98,"value":191691.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $11.90 to $12.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":21247,"source":{"system":"sec-edgar","filing":"0001385508-19-000039","document":"wf-form4_155475763759980.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000039/wf-form4_155475763759980.xml","form_type":"4"}},{"id":3560091,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-04-08T17:07:32.000Z","date":"2019-04-05","kind":"exercise","acquired":true,"shares":21472,"price":7.25,"value":155672.0,"ownership":{"direct":true},"balance_after":37248,"source":{"system":"sec-edgar","filing":"0001385508-19-000039","document":"wf-form4_155475763759980.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000039/wf-form4_155475763759980.xml","form_type":"4"}},{"id":3562442,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option","published_at":"2019-04-04T16:35:43.000Z","date":"2019-04-04","kind":"exercise","acquired":false,"shares":22557,"price":7.25,"value":163538.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of three trials on or subsequent to October 23, 2015; or (B) (1) the approval by the U.S. Food and Drug Administration of the New Drug Application with respect to the opioid overdose reversal treatment; and (2) the commencement of two trials on or subsequent to October 23, 2015; and (ii) the Expiration Date."}],"balance_after":396472,"derivative":{"exercise_price":7.25,"exercise_date":"2015-10-27","expiration_date":"2025-10-26","underlying":"Common Stock","underlying_shares":22557},"source":{"system":"sec-edgar","filing":"0001385508-19-000037","document":"wf-form4_155441012914575.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000037/wf-form4_155441012914575.xml","form_type":"4"}},{"id":3562441,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option","published_at":"2019-04-04T16:35:43.000Z","date":"2019-04-03","kind":"exercise","acquired":false,"shares":5149,"price":7.25,"value":37330.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of three trials on or subsequent to October 23, 2015; or (B) (1) the approval by the U.S. Food and Drug Administration of the New Drug Application with respect to the opioid overdose reversal treatment; and (2) the commencement of two trials on or subsequent to October 23, 2015; and (ii) the Expiration Date."}],"balance_after":419029,"derivative":{"exercise_price":7.25,"exercise_date":"2015-10-27","expiration_date":"2025-10-26","underlying":"Common Stock","underlying_shares":5149},"source":{"system":"sec-edgar","filing":"0001385508-19-000037","document":"wf-form4_155441012914575.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000037/wf-form4_155441012914575.xml","form_type":"4"}},{"id":3562440,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option","published_at":"2019-04-04T16:35:43.000Z","date":"2019-04-02","kind":"exercise","acquired":false,"shares":822,"price":7.25,"value":5959.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of three trials on or subsequent to October 23, 2015; or (B) (1) the approval by the U.S. Food and Drug Administration of the New Drug Application with respect to the opioid overdose reversal treatment; and (2) the commencement of two trials on or subsequent to October 23, 2015; and (ii) the Expiration Date."}],"balance_after":424178,"derivative":{"exercise_price":7.25,"exercise_date":"2015-10-27","expiration_date":"2025-10-26","underlying":"Common Stock","underlying_shares":822},"source":{"system":"sec-edgar","filing":"0001385508-19-000037","document":"wf-form4_155441012914575.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000037/wf-form4_155441012914575.xml","form_type":"4"}},{"id":3562439,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-04-04T16:35:43.000Z","date":"2019-04-04","kind":"sale","acquired":false,"shares":16836,"price":11.93,"value":200853.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $11.90 to $12.08. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":15776,"source":{"system":"sec-edgar","filing":"0001385508-19-000037","document":"wf-form4_155441012914575.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000037/wf-form4_155441012914575.xml","form_type":"4"}},{"id":3562438,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-04-04T16:35:43.000Z","date":"2019-04-04","kind":"exercise","acquired":true,"shares":22557,"price":7.25,"value":163538.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."}],"balance_after":32612,"source":{"system":"sec-edgar","filing":"0001385508-19-000037","document":"wf-form4_155441012914575.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000037/wf-form4_155441012914575.xml","form_type":"4"}},{"id":3562437,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-04-04T16:35:43.000Z","date":"2019-04-03","kind":"sale","acquired":false,"shares":3791,"price":12.24,"value":46401.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $12.22 to $12.47. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":10055,"source":{"system":"sec-edgar","filing":"0001385508-19-000037","document":"wf-form4_155441012914575.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000037/wf-form4_155441012914575.xml","form_type":"4"}},{"id":3562436,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-04-04T16:35:43.000Z","date":"2019-04-02","kind":"sale","acquired":false,"shares":600,"price":12.48,"value":7488.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $12.47 to $12.52. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":13846,"source":{"system":"sec-edgar","filing":"0001385508-19-000037","document":"wf-form4_155441012914575.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000037/wf-form4_155441012914575.xml","form_type":"4"}},{"id":3562435,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-04-04T16:35:43.000Z","date":"2019-04-03","kind":"exercise","acquired":true,"shares":5149,"price":7.25,"value":37330.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."}],"balance_after":14446,"source":{"system":"sec-edgar","filing":"0001385508-19-000037","document":"wf-form4_155441012914575.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000037/wf-form4_155441012914575.xml","form_type":"4"}},{"id":3562434,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-04-04T16:35:43.000Z","date":"2019-04-02","kind":"exercise","acquired":true,"shares":822,"price":7.25,"value":5959.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."}],"balance_after":9297,"source":{"system":"sec-edgar","filing":"0001385508-19-000037","document":"wf-form4_155441012914575.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000037/wf-form4_155441012914575.xml","form_type":"4"}},{"id":3692615,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-17T16:18:31.000Z","date":"2019-01-15","kind":"grant","acquired":true,"shares":13200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 15, 2019, the reporting person was granted an option to purchase 13,200 shares of common stock. The option vests as follows: 1/48 of the options become exercisable on the first monthly anniversary of the vesting commencement date, and 1/48 of the options become exercisable on such date every month thereafter through the fourth anniversary of the Grant Date."}],"balance_after":13200,"derivative":{"exercise_price":14.62,"expiration_date":"2029-01-14","underlying":"Common Stock","underlying_shares":13200},"source":{"system":"sec-edgar","filing":"0001385508-19-000012","document":"wf-form4_154775989523176.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000012/wf-form4_154775989523176.xml","form_type":"4"}},{"id":3699922,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option","published_at":"2019-01-08T16:51:14.000Z","date":"2019-01-04","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":6,"exercise_date":"2013-12-31","expiration_date":"2023-12-30","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001385508-19-000008","document":"wf-form4_154698425748836.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000008/wf-form4_154698425748836.xml","form_type":"4"}},{"id":3699921,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option","published_at":"2019-01-08T16:51:14.000Z","date":"2019-01-07","kind":"exercise","acquired":false,"shares":8641,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":425000,"derivative":{"exercise_price":7.25,"exercise_date":"2015-10-27","expiration_date":"2025-10-26","underlying":"Common Stock","underlying_shares":8641},"source":{"system":"sec-edgar","filing":"0001385508-19-000008","document":"wf-form4_154698425748836.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000008/wf-form4_154698425748836.xml","form_type":"4"}},{"id":3699920,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option","published_at":"2019-01-08T16:51:14.000Z","date":"2019-01-04","kind":"exercise","acquired":false,"shares":16359,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":433641,"derivative":{"exercise_price":7.25,"exercise_date":"2015-10-27","expiration_date":"2025-10-26","underlying":"Common Stock","underlying_shares":16359},"source":{"system":"sec-edgar","filing":"0001385508-19-000008","document":"wf-form4_154698425748836.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000008/wf-form4_154698425748836.xml","form_type":"4"}},{"id":3699919,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-01-08T16:51:14.000Z","date":"2019-01-08","kind":"sale","acquired":false,"shares":11407,"price":13.27,"value":151370.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $13.05 to $13.42. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":8475,"source":{"system":"sec-edgar","filing":"0001385508-19-000008","document":"wf-form4_154698425748836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000008/wf-form4_154698425748836.xml","form_type":"4"}},{"id":3699918,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-01-08T16:51:14.000Z","date":"2019-01-07","kind":"sale","acquired":false,"shares":26759,"price":13.28,"value":355359.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $13.22 to $13.50. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":19882,"source":{"system":"sec-edgar","filing":"0001385508-19-000008","document":"wf-form4_154698425748836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000008/wf-form4_154698425748836.xml","form_type":"4"}},{"id":3699917,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-01-08T16:51:14.000Z","date":"2019-01-07","kind":"exercise","acquired":true,"shares":25000,"price":6,"value":150000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."}],"balance_after":46641,"source":{"system":"sec-edgar","filing":"0001385508-19-000008","document":"wf-form4_154698425748836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000008/wf-form4_154698425748836.xml","form_type":"4"}},{"id":3699916,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-01-08T16:51:14.000Z","date":"2019-01-07","kind":"exercise","acquired":true,"shares":8641,"price":7.25,"value":62647.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."}],"balance_after":21641,"source":{"system":"sec-edgar","filing":"0001385508-19-000008","document":"wf-form4_154698425748836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000008/wf-form4_154698425748836.xml","form_type":"4"}},{"id":3699915,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-01-08T16:51:14.000Z","date":"2019-01-04","kind":"sale","acquired":false,"shares":11834,"price":13.54,"value":160232.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $13.47 to $13.66. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":13000,"source":{"system":"sec-edgar","filing":"0001385508-19-000008","document":"wf-form4_154698425748836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000008/wf-form4_154698425748836.xml","form_type":"4"}},{"id":3699914,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-01-08T16:51:14.000Z","date":"2019-01-04","kind":"exercise","acquired":true,"shares":16359,"price":7.25,"value":118602.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."}],"balance_after":24834,"source":{"system":"sec-edgar","filing":"0001385508-19-000008","document":"wf-form4_154698425748836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550819000008/wf-form4_154698425748836.xml","form_type":"4"}},{"id":3793475,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-10-10T16:12:19.000Z","date":"2018-10-09","kind":"sale","acquired":false,"shares":6941,"price":17.04,"value":118274.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."}],"balance_after":8475,"source":{"system":"sec-edgar","filing":"0001385508-18-000091","document":"wf-form4_153920232327206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550818000091/wf-form4_153920232327206.xml","form_type":"4"}},{"id":3793474,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-10-10T16:12:19.000Z","date":"2018-10-08","kind":"sale","acquired":false,"shares":3059,"price":17.33,"value":53012.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."}],"balance_after":15416,"source":{"system":"sec-edgar","filing":"0001385508-18-000091","document":"wf-form4_153920232327206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550818000091/wf-form4_153920232327206.xml","form_type":"4"}},{"id":3793473,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-10-10T16:12:19.000Z","date":"2018-10-05","kind":"sale","acquired":false,"shares":847,"price":18.14,"value":15364.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."}],"balance_after":18475,"source":{"system":"sec-edgar","filing":"0001385508-18-000091","document":"wf-form4_153920232327206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550818000091/wf-form4_153920232327206.xml","form_type":"4"}},{"id":3796583,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option","published_at":"2018-10-04T16:47:33.000Z","date":"2018-10-02","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the Stock Option Agreement, the number of shares issued on a cashless basis is determined by the following formula: Number of shares = (number of options times (prior day closing stock price less exercise price)) divided by the prior day closing stock price."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Pursuant to the Stock Option Agreement, the number of shares issued on a cashless basis is determined by the following formula: Number of shares = (number of options times (prior day closing stock price less exercise price)) divided by the prior day closing stock price."}],"balance_after":450000,"derivative":{"exercise_price":7.25,"exercise_date":"2015-10-27","expiration_date":"2025-10-26","underlying":"Common Stock","underlying_shares":29297},"source":{"system":"sec-edgar","filing":"0001385508-18-000086","document":"wf-form4_153868603565432.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550818000086/wf-form4_153868603565432.xml","form_type":"4"}},{"id":3796582,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-10-04T16:47:33.000Z","date":"2018-10-04","kind":"sale","acquired":false,"shares":4006,"price":18.43,"value":73830.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."}],"balance_after":19322,"source":{"system":"sec-edgar","filing":"0001385508-18-000086","document":"wf-form4_153868603565432.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550818000086/wf-form4_153868603565432.xml","form_type":"4"}},{"id":3796581,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-10-04T16:47:33.000Z","date":"2018-10-03","kind":"sale","acquired":false,"shares":4300,"price":19.23,"value":82689.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $19.00 to $19.75. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":23328,"source":{"system":"sec-edgar","filing":"0001385508-18-000086","document":"wf-form4_153868603565432.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550818000086/wf-form4_153868603565432.xml","form_type":"4"}},{"id":3796580,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-10-04T16:47:33.000Z","date":"2018-10-02","kind":"sale","acquired":false,"shares":10144,"price":17.51,"value":177621.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."}],"balance_after":27628,"source":{"system":"sec-edgar","filing":"0001385508-18-000086","document":"wf-form4_153868603565432.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550818000086/wf-form4_153868603565432.xml","form_type":"4"}},{"id":3796579,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-10-04T16:47:33.000Z","date":"2018-10-02","kind":"exercise","acquired":true,"shares":29297,"price":7.25,"value":212403.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person."}],"balance_after":37772,"source":{"system":"sec-edgar","filing":"0001385508-18-000086","document":"wf-form4_153868603565432.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000138550818000086/wf-form4_153868603565432.xml","form_type":"4"}},{"id":4486193,"issuer":{"id":115992,"kind":"organization","name":"OPIANT PHARMACEUTICALS, INC.","symbol":"OPNT"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-01-19T10:56:58.000Z","date":"2017-01-17","kind":"purchase","acquired":true,"shares":3475,"price":6.99,"value":24290.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.955 to $7.00, inclusive."}],"balance_after":8475,"source":{"system":"sec-edgar","filing":"0001144204-17-002837","document":"v457160_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385508/000114420417002837/v457160_4.xml","form_type":"4"}}]}